---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-008294"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2025-05-30T23:59:59+00:00"
generated_at: "2026-05-20T04:17:17.099272+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Coherus BioSciences renames to Coherus Oncology, sharpens focus on cancer immunotherapy

## Summary
- Name change to Coherus Oncology, Inc. effective May 29, 2025; stock ticker CHRS unchanged.
- Company now exclusively focused on proprietary immuno-oncology medicines; pipeline includes LOQTORZI, CHS-114, and casdozokitug.
- LOQTORZI is a next-gen PD-1 inhibitor approved for nasopharyngeal carcinoma; CHS-114 is a CCR8 antibody in Phase 1b.
- Casdozokitug, an IL-27 antagonist, is in a randomized Phase 2 study for first-line advanced metastatic HCC.
- Board and scientific advisors include leaders from Cancer Research Institute, MSKCC, and HHMI.

## SEC filing metadata
- accession: 0001558370-25-008294
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2025-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837025008294/0001558370-25-008294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837025008294/chrs-20250529x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-008294
- JSON: https://secwatch.observer/filing/0001558370-25-008294.json
- Plain text: https://secwatch.observer/filing/0001558370-25-008294.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.